Includes a guide for troubleshooting of film-coated products Lists trademarked ingredients and equipment for film coating Presents a checklist for a QC coating-defect reporting program This book is a complete, authoritative resource on the coating of tablets, capsules, and other solid dosage forms of therapeutic agents. Fourteen authors cover the industry's technologies. The book begins with a full discussion of the primary processes -- sugar coating, film coating, and microencapsulation -- as well as the rationale for coating, methodologies, formulations, processing methods, and equipment and cleaning. Then it explores automation of the coating process, including hardware and software requirements. Finally, the book examines major stability and quality control issues. Regulations underlie all discussions.

This book is a complete, authoritative resource on the coating of tablets, capsules, and other solid dosage forms of therapeutic agents. Fourteen authors cover the industry's technologies. The book begins with a full discussion of the primary processes -- sugar coating, film coating, and microencapsulation -- as well as the rationale for coating, methodologies, formulations, processing methods, and equipment and cleaning. Then it explores automation of the coating process, including hardware and software requirements. Finally, the book examines major stability and quality control issues. Regulations underlie all discussions.

The objective of the study was to develop a controlled release dosage form of insulin, which can provide basal concentrations of insulin in diabetic rats for 1 to 2 weeks after a single subcutaneous injection. A biodegradable injectable drug delivery gel was prepared by dissolving a biodegradable polymer, polylactic-co-glycolic acid (PLGA), in biocompatible plasticizer(s), triethyl citrate (TEe and/or acetyl triethyl citrate (ATEe. Insulin or modified insulin was then loaded into the blank gel to form insulin or modified insulin suspension in the polymer solution. After the insulin-loaded gel was injected subcutaneously, the insulin or modified insulin was released slowly from the depot by a combination of drug diffusion and erosion of the polymer. The formulation prepared with 5% PLGA, ATEu TEC (3:1) and 4% modified insulin glargine was able to suppress the blood glucose concentrations of the ZDF rats significantly for 10 days after a single subcutaneous injection. The addition of zinc sulfate to the formulations prepared with purified insulin glargine particles further slowed down the drop in blood glucose concentrations.